Black Diamond co-founders David Epstein (L) and Elizabeth Buck
April 25, 2022 10:22 AM EDT
People
R&D

Black Di­a­mond lays off 30% of its work­force and culls a drug from its 'Mas­terKey' chest

Kyle LaHucik

Senior Reporter

With every round of lay­offs, the dol­drums of the biotech bear mar­ket get ever dark­er and more de­press­ing. Black Di­a­mond Ther­a­peu­tics is the lat­est to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times